Company Encyclopedia
View More
name
Galectin Therap
GALT.US
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc.
1.946 T
GALT.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    10X Fund, L.P. Reports Disposal of Galectin Therapeutics Inc. Common Shares

    10X Fund, L.P. has reported the disposal of common shares of Galectin Therapeutics Inc. The filing was made by multiple reporting persons, including 10X Fund, L.P. The original content was published by Galectin Therapeutics Inc. via the SEC's EDGAR system.

    Reuters·
    US
    GALT
    +10.53%
    Reuters·
    US
    GALT
    +10.53%

    Galectin Therapeutics Inc. Publishes Transcript of NAVIGATE Trial Update Event

    Galectin Therapeutics Inc. has released a transcript of its NAVIGATE trial update event, highlighting significant achievements, near completion of trial analyses, and discussions with potential partners for belapectin. The company plans to unblind the trial by end of 2024 and engage with scientific and investor communities through various events. The CEO expressed excitement about the company's progress and acknowledged the efforts of all contributors. The full transcript is available online.

    Reuters·
    US
    GALT
    +10.53%
    Reuters·
    US
    GALT
    +10.53%

    Galectin Therapeutics Chief Medical Officer Jamil Khurram Reports Disposal of Common Shares

    Jamil Khurram, Chief Medical Officer of Galectin Therapeutics Inc., reported a disposal of common shares of the company. The full filing is available via EDGAR, the U.S. SEC's system, with Ref. ID: 0001133416-25-000054, dated November 14, 2025.

    Reuters·
    US
    GALT
    +10.53%
    Reuters·
    US
    GALT
    +10.53%

    Promising Phase 2 Data Boosts Confidence in Galectin Therapeutics’ Belapectin for Fibrotic Disease Treatment

    Matthew Keller from H.C. Wainwright reiterated a Buy rating for Galectin Therapeutics with a $6.00 price target, citing promising Phase 2 data for belapectin in treating fibrotic diseases. The NAVIGATE study showed belapectin reduced new varices in high-risk ELF fibrosis patients and decreased key liver fibrosis biomarkers, supporting its therapeutic benefits and anti-fibrotic properties. This data boosts confidence in the stock's growth potential.

    Tip Ranks·
    US
    GALT
    +10.53%
    Tip Ranks·
    US
    GALT
    +10.53%

    Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update

    NORCROSS, Ga., Nov. 14, 2025 ( GLOBE NEWSWIRE ) -- Galectin Therapeutics, Inc. ( NASDAQ: GALT ) , the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three and nine months ended September 30, 2025.

    GlobeNewswire·
    US
    GALT
    +10.53%
    GlobeNewswire·
    US
    GALT
    +10.53%
    © 2025 Longbridge｜Disclaimer